More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

In the first part of this two-part series, In Vivo discussed the potential for organs on chips to revolutionize drug development. However, great challenges wait for developers of the technology.